Lymphangiogenesis and breast cancer metastasis

Histology and Histopathology

Volumn 17, Issue 3, 2002, Pages 863-870

  Cunnick, Giles H ^a   Jiang, W G ^a   Gomez, K F ^a   Mansel, R E ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; Lymphangiogenesis; LYVE 1; Metastasis

Indexed keywords

HOMEOBOX PROSPERO LIKE PROTEIN; HOMEODOMAIN PROTEIN; LYMPHATIC VESSEL ENDOTHELIUM MARKER; PODOPLANIN; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; BLOOD VESSEL; BREAST CANCER; CANCER INVASION; CANCER RESEARCH; ENDOTHELIUM; FEMALE; HISTOGENESIS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; LYMPHATIC SYSTEM; METASTASIS; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; REVIEW; TUMOR CELL; WESTERN HEMISPHERE;

BREAST NEOPLASMS; FEMALE; GLYCOPROTEINS; HUMANS; HYALURONIC ACID; LYMPHATIC SYSTEM; MEMBRANE GLYCOPROTEINS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL;

PROSPERO;

EID: 0036068829     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
2. CD44 is the principal cell surface receptor for hyaluronate
3. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan
4. Clinical trials in metastatic breast cancer to bone: Past-present-future
5. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis
6. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium
7. Vascular endothelial growth factor C induces angiogenesis in vivo
8. Relation of tumour size, lymph node status and survival in 24,740 breast cancer cases
9. Neoplasia
10. Quantification of lymphangiogenesis with real-time quantitative PCR, using breast cancer as a model
11. Expression and quantitation of lymphatic endothelial marker, LYVE-1, mRNA in breast cancer
12. Proposal for a new model of breast cancer metastatic development
13. Studies correlating the growth rate of a tumour and its metastases and providing evidence for tumour related systemic growth retarding factors
14. Direct resorption of bone by breast cancer cells in vitro
15. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum growth factor. Oncoproteins and hypoxia
16. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer
17. Location of breast carcinoma and prognosis
18. Relation of number of positive nodes to the prognosis of patients with primary breast cancer. An N.S.A.B.P. update
19. Pathobiologic consideration in the treatment of breast cancer
20. The incidence of breast cancer: The global burden, public health considerations
21. Uptake and degradation of hyaluronan in lymphatic tissue
22. Platelet tumor interactions in mice. The role of platelets in the spread of malignant disease
23. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: Subanalysis in node-positive and node-negative patients
24. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast
25. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers
26. Openings between defective endothelial cells explain tumor vessel leakiness
27. Integrins: Versatility, modulation and signalling in cell adhesion
28. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
29. Metastatic cascade, molecular/cellular events and new therapeutic opportunities
30. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
31. Vascular endothelial growth factors in the regulation of angiogenesis and lymphangiogenesis
32. Breast cancer metastasis
33. Inhibition of lymphagiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3
34. Vascular endothelial growth factor-C-mediated lymphagiogenesis promotes tumour metastasis
35. Cancer progression and growth; Relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis
36. Prox1, a prospero-related homeobox gene expressed during mouse development
37. Intravenous saline infusion in rat increases hyaluronan efflux in intestinal lymph by increasing lymph flow
38. From angiogenesis to lymphangiogenesis
39. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis
40. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
41. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity
42. Molecular frameworks for angiogenesis: A complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines
43. The immunoglobulin superfamily
44. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
45. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics
46. The cadherin superfamily
47. Reduction in mortality from breast cancer after mass screening with mammography
48. The selectins and their ligands
49. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
50. Localisation of parathyroid hormone related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridisation
51. Treatment of the axilla in patients with screen-detected breast cancer
52. Intratumoral microvessel density as a prognostic factor in cancer
53. Prox1 function is required for the development of the murine lymphatic system
54. Cancer statistics. CA
55. Dominant negative blockade of the transforming growth factor β (TGFβ) type II receptor decreases breast cancer mediated osteolysis